Roth Capital Upgrades QLT Inc (QLTI) to Buy

Roth Capital upgraded QLT Inc (NASDAQ: QLTI) from Neutral to Buy with a price target of $5.50 (from $4.50).

Analyst Scott Henry commented, "We are upgrading shares of QLTI to Buy from Neutral post the proposed acquisition of INSV. We believe that QLTI's financial resources could unlock the value in this emerging eyecare company. Further, we now view QLTI as a sustainable ophthalmology company that could have increased enterprise value. Price target increased to $5.50/share from $4.50."

For an analyst ratings summary and ratings history on QLT Inc click here. For more ratings news on QLT Inc click here.

Shares of QLT Inc closed at $3.99 yesterday.

You May Also Be Interested In

• Lake Street Downgrades Identiv, Inc. (INVE) to Hold
• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $40 at Guggenheim
• Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim